FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, D.C. 20549 | n, D.C. 20549 |
|------------------------|---------------|
|------------------------|---------------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|--|
| | 3235-0287 | | | | | | | | | | |
| Estimated average burden | | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(h)

| mstruc | don 1(b). | | | Filed | | | | | | | ompany Act of | | 1934 | | | | | | | |
|--|---|---|-----------------|--|--|--|---|------------------------------|----------------|---------------------------------|--------------------|--|--|-------|---|---|-----------------------------------|---|-------------------------------|--|
| | | | | | | 2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [BDTX] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner | | | | | |
| (Last) (First) (Middle) ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1 | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 10/27/2022 | | | | | | | | | belov | | | Other (below) | | |
| (Street) CURACAO P8 00000 | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person | | | | | |
| (City) | (St | | Zip) | D i | 4: | | | | | | | | | | | 1 | | | | |
| Date | | | 2. Transacti | saction 2A. I Exec I/Day/Year) if an | | 2A. Deemed Execution Date, | | 3. Transa Code (8) | ction | 4. Securities Acquired (A) | | | or 5. Am Secu Bene Owne | | ount of ties cially I Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Pri | ce | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | |
| Common | Stock | | | 10/27/2022 | | 2 | | P | | 191,678 | A | \$1 | \$1.8741 5,10 | | ,105,064 | | D | | | |
| Common | Stock | | | 10/28/2022 | | | | | P | | 172,974 | A | \$2 | .1793 | 5,2 | 78,038 | D | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of | 3. Transaction Date (Month/Day/Year) | 3A. Do Execu | (e.g., pu eemed ution Date, | ve Securities Adts, calls, warrar 4. Transaction Code (Instr. 8) 5. Num of Derivat Securit | | ants, umber | optic | e Exer | convertib cisable and ate | | | 8. Price of Derivative Security Securities | | 9. Number derivative Securities Beneficiall | Ownership Form: | Beneficial Ownership t (Instr. 4) | | | |
| (1113111. 3) | Derivative Security | | (MOIII | (monumbuy) reary | | | Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | | | Derivative Security (In 3 and 4) | | - 1 | Owned Following Reported Transactic (Instr. 4) | | | or Indired (I) (Instr. | or Indirect (I) (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exerci | sable | Expiration Date | | Amou or Numb of Share | er | | | | | | |
| | | f Reporting Person [*] DWTH N V | ŧ | | | | | | | | | | | | | | | | | |
| | | (First) UILDING, UNIT | • | Middle) | | | | | | | | | | | | | | | | |
| (Street) | AO | P8 | 00 | 0000 | | | | | | | | | | | | | | | | |
| (City) | | (State) | (Z | ip) | | | | | | | | | | | | | | | | |
| | nd Address of | f Reporting Person [*] | r | | | | | | | | | | | | | | | | | |
| (Last) SCHWE | RTSTRAS | (First) SE 6 | (N | 1iddle) | | | | | | | | | | | | | | | | |
| (Street) | FHAUSEN | V8 | C | H-8200 | | - | | | | | | | | | | | | | | |

Explanation of Responses:

(State)

(Zip)

(City)

Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Black Diamond Therapeutics, Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.

10/31/2022 /s/ Ivo Betschart /s/ Martin Gubler 10/31/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.